Article
A Novel Hyperinflammation Clinical Risk Tool, HI5-NEWS2, Predicts Mortality Following Early Dexamethasone Use in an Observational Cohort of Hospitalised COVID-19 Patients
2021-05-27
Abstract excerpt
Background: The success of early dexamethasone therapy for hospitalised COVID-19 cases in treatment of Sars-CoV-2 infection may predominantly reflect its anti-inflammatory action against a hyperinflammation (HI) response. It is likely that there is substantial heterogeneity in HI responses in COVID-19.<br><br>Methods: Blood CRP, ferritin, neutrophil, lymphocyte and platelet counts were scored to assess HI (HI5) an...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7b336a8c-f01b-5e2b-b231-1e539832d5ca
- DOI
- 10.2139/ssrn.3854746
